Drugs Containing Excipient (Inactive Ingredient) DEHYDRATED ALCOHOL

Branded drugs containing DEHYDRATED ALCOHOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SpringWorks Therapeutics Inc	GOMEKLI	mirdametinib	82448-130	DEHYDRATED ALCOHOL	2041-02-17
Xcovery Holdings Inc	ENSACOVE	ensartinib	83076-1025	DEHYDRATED ALCOHOL	2031-11-29
Zhuhai Beihai Biotech Co Ltd	BEIZRAY	docetaxel	83513-009	DEHYDRATED ALCOHOL
Avyxa Pharma LLC	FRINDOVYX	cyclophosphamide	83831-119	DEHYDRATED ALCOHOL
Avyxa Pharma LLC	AVOPEF	etoposide	83831-144	DEHYDRATED ALCOHOL

Generic drugs containing DEHYDRATED ALCOHOL excipient

Company	Ingredient	NDC	Excipient
Armstrong Pharmaceuticals Inc	ipratropium bromide inhalation	17270-0401	DEHYDRATED ALCOHOL
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	trimethobenzamide hydrochloride	23155-180	DEHYDRATED ALCOHOL
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	docetaxel	23155-903	DEHYDRATED ALCOHOL
Camber Pharmaceuticals Inc	dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate	31722-185	DEHYDRATED ALCOHOL
DrReddys Laboratories Inc	dabigatran etexilate	43598-642	DEHYDRATED ALCOHOL

Dehydrated Alcohol Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 2, 2026

Dehydrated alcohol, also called absolute ethanol or anhydrous ethanol, is a high-purity pharmaceutical solvent used in oral liquids, injections, topical products, inhalation products, extracts, and manufacturing processes. Its market is mature, fragmented, and price-sensitive. Demand is supported by injectable and topical drug production, pharmaceutical-grade antiseptics, botanical extraction, and solvent replacement requirements. Financial performance depends more on ethanol feedstock prices, energy costs, denaturant controls, regulatory compliance, and supply continuity than on patent exclusivity.

Dehydrated alcohol generally does not have a conventional innovative-drug patent estate. The principal commercial barriers are pharmacopoeial compliance, validated manufacturing, impurity control, hazardous-material logistics, and customer qualification.

What is dehydrated alcohol in pharmaceutical manufacturing?

Dehydrated alcohol is ethanol containing very low water levels. In the United States, the United States Pharmacopeia identifies the material as Alcohol, Dehydrated. The product is typically manufactured at approximately 99% ethanol by volume or higher, with the exact specification determined by the applicable pharmacopoeial monograph and customer requirements.[1]

The material is used as:

• A solvent for active pharmaceutical ingredients
• A co-solvent in oral and topical liquids
• A carrier in sprays and aerosols
• A process solvent for extraction and crystallization
• An antimicrobial component in selected formulations
• A cleaning or processing agent in pharmaceutical manufacturing

Its commercial role differs from that of ordinary industrial ethanol. Pharmaceutical buyers require documented control of water, methanol, aldehydes, ketones, benzene, nonvolatile residues, heavy metals, microbial quality, and trace contaminants.

Is dehydrated alcohol an excipient or an active ingredient?

Dehydrated alcohol can be an excipient or an active ingredient depending on the product and labeling framework.

In a liquid formulation, ethanol may function as a solvent or co-solvent and therefore be listed as an inactive ingredient. In antiseptic products, ethanol may be the active ingredient. FDA’s temporary and final regulatory frameworks for alcohol-based hand sanitizers distinguish ethanol as an active substance when the product makes antiseptic claims.[2]

The same chemical substance can therefore have different regulatory treatment:

Use	Typical regulatory role
Oral solution solvent	Excipient
Topical drug solvent	Excipient or active ingredient
Hand sanitizer	Active ingredient
Botanical extract production	Process solvent
Injectable formulation	Excipient, subject to route-specific safety controls
Manufacturing equipment cleaning	Process or cleaning agent

What pharmaceutical applications drive dehydrated alcohol demand?

Demand is broad because ethanol is used across multiple dosage forms and manufacturing operations.

Oral and liquid formulations

Ethanol improves solubility for active ingredients with limited water solubility. It is commonly used in oral solutions, elixirs, cough preparations, concentrated drops, and certain pediatric or geriatric products. Its use is constrained by alcohol exposure limits, taste, labeling requirements, and patient population.

Formulators may replace ethanol with propylene glycol, glycerin, polyethylene glycol, or surfactant systems when alcohol content is commercially or clinically undesirable. This creates substitution risk in oral liquids.

Topical and dermatological products

Topical sprays, rubs, antiseptic solutions, and dermatological preparations are important demand segments. Ethanol provides rapid evaporation and can improve delivery of dissolved ingredients.

The topical segment is exposed to consumer and regulatory pressure over flammability, skin irritation, and product claims. Pharmaceutical-grade ethanol competes with isopropyl alcohol in some applications, but the two materials are not interchangeable for every formulation or regulatory use.

Injectable products

Ethanol is used as a co-solvent in selected injectable formulations, particularly where active ingredients have limited aqueous solubility. Injectable applications have high qualification barriers because residual solvent levels, extractables, leachables, particulate matter, endotoxin controls, and container compatibility must be demonstrated.

This segment has lower volume than industrial solvent markets but higher quality requirements and stronger supplier retention.

Botanical and pharmaceutical extraction

Ethanol is widely used to extract botanical compounds, active pharmaceutical ingredients, flavors, and natural products. Dehydrated alcohol can be blended with purified water to achieve a targeted extraction polarity.

Demand from botanical products is sensitive to consumer preferences, supplement regulation, contract manufacturing activity, and the growth of plant-derived pharmaceutical ingredients.

Inhalation, spray, and aerosol systems

Ethanol can act as a carrier or co-solvent in inhalation and spray products. These applications require careful control of flammability, vapor pressure, residual impurities, and device compatibility.

How large is the pharmaceutical dehydrated alcohol market?

There is no single authoritative public market-size series for pharmaceutical-grade dehydrated alcohol as a standalone category. Commercial datasets often combine pharmaceutical ethanol with industrial, beverage, cosmetic, laboratory, and fuel ethanol. Those categories have different specifications and economics.

The pharmaceutical segment is best analyzed through procurement and production indicators:

1. Pharmaceutical manufacturing volumes
2. Demand for liquid, topical, and spray dosage forms
3. Injectable formulation activity
4. Alcohol-based antiseptic production
5. Botanical extraction capacity
6. Regulatory qualification of pharmaceutical suppliers
7. Ethanol and energy input costs

Pharmaceutical-grade demand is much smaller than total ethanol demand but has higher unit economics because customers pay for specification control, quality documentation, validated production, packaging, and supply reliability.

What determines the price of dehydrated alcohol?

The main price variables are:

Cost driver	Financial effect
Corn, sugarcane, or other ethanol feedstock	Changes base ethanol cost
Natural gas and electricity	Affects distillation and dehydration cost
Molecular sieve or azeotropic dehydration	Adds processing cost
Denaturant requirements	Changes product qualification and use
Water and impurity testing	Raises quality-control expense
Hazardous-goods packaging	Increases logistics cost
Excise taxes and alcohol controls	Can materially affect delivered price
Energy and freight markets	Affect regional price differences
Customer audit and validation requirements	Raises fixed supplier costs

The price spread between technical-grade and pharmaceutical-grade ethanol reflects more than purity. It includes batch documentation, quality systems, regulatory support, retained samples, change-control procedures, audit access, and validated transport.

What is the financial trajectory for pharmaceutical dehydrated alcohol?

The financial trajectory is structurally stable rather than patent-driven. Revenue growth typically follows pharmaceutical production and formulation demand, while margins move with feedstock and energy prices.

Base-case trajectory

The base case is moderate volume growth with periodic price volatility. Pharmaceutical demand should remain resilient because ethanol is embedded in established formulations and manufacturing processes. Growth is likely to be slower than in high-growth pharmaceutical excipient categories such as advanced drug-delivery polymers, lipid nanoparticles, or specialized biologic stabilizers.

Profitability depends on procurement discipline and product mix. Suppliers with validated pharmaceutical plants, global distribution, and strong quality documentation can earn a premium over commodity ethanol sellers.

Upside drivers

Potential upside comes from:

• Growth in topical and antiseptic products
• Expansion of liquid and spray dosage forms
• Higher use of botanical extraction
• Increased outsourcing to contract development and manufacturing organizations
• Demand for low-impurity solvents in complex drug products
• Regional pharmaceutical capacity expansion
• Supply-chain diversification away from single-country sourcing

Downside drivers

The principal downside risks are:

• Substitution by propylene glycol, glycerin, or other solvents
• Lower demand for alcohol-containing pediatric products
• Declining antiseptic demand after pandemic-related inventory normalization
• Ethanol overcapacity
• Feedstock price increases that cannot be passed through
• New restrictions on alcohol exposure or packaging
• Product recalls caused by methanol or other contamination
• Transport restrictions for flammable liquids

Which companies supply pharmaceutical-grade dehydrated alcohol?

The competitive field includes large ethanol producers, pharmaceutical raw-material suppliers, specialty chemical distributors, and regional alcohol manufacturers. Supplier identity varies by geography because alcohol production is subject to tax, excise, customs, and hazardous-material controls.

Common supplier categories include:

Integrated ethanol producers

These companies manufacture ethanol from agricultural or petrochemical feedstocks and may operate dehydration, purification, and packaging assets. Their advantage is feedstock access and scale. Their exposure is high sensitivity to commodity cycles.

Pharmaceutical excipient manufacturers

These suppliers focus on pharmacopoeial materials, batch documentation, quality systems, and customer qualification. They may buy bulk ethanol and perform final purification, packaging, and release testing.

Specialty distributors

Distributors provide smaller package sizes, regional inventory, technical support, and regulatory documentation. Their margins are generally higher per unit, but they carry inventory and hazardous-goods costs.

Contract manufacturers

Some pharmaceutical manufacturers purchase bulk dehydrated alcohol directly and qualify multiple sources. Others rely on contract manufacturers that manage formulation, solvent handling, and supplier release.

A supplier’s competitive position is strongest when it can provide:

• USP, Ph. Eur., or JP compliance
• Current Good Manufacturing Practice controls
• Certificate of Analysis for every batch
• Elemental impurity and volatile impurity data
• Change-control notifications
• Global regulatory support
• Validated packaging and transport
• Continuity of supply during ethanol-market disruptions

What regulatory status applies to dehydrated alcohol?

Dehydrated alcohol is regulated through multiple overlapping frameworks rather than a single pharmaceutical approval.

United States

The applicable framework can involve:

• United States Pharmacopeia monograph compliance
• FDA drug manufacturing requirements
• 21 C.F.R. Parts 210 and 211 for finished-drug manufacturing
• FDA inactive-ingredient review where used as an excipient
• Alcohol and Tobacco Tax and Trade Bureau controls
• Hazard communication and flammable-liquid requirements
• Product-specific labeling and dosage restrictions

FDA’s Inactive Ingredient Database can provide evidence of prior use in approved drug products, but listing does not create a blanket approval for every route, concentration, or patient population.[3]

Europe

European manufacturers may use ethanol complying with the European Pharmacopoeia and applicable EU pharmaceutical quality requirements. Supplier qualification, excipient risk assessment, traceability, and change control remain central.

The European Commission’s excipient guidance places responsibility on manufacturers to assess excipient quality and the risk profile associated with the finished medicinal product.[4]

Japan and other markets

Japan generally relies on Japanese Pharmacopoeia or recognized international standards, while other jurisdictions may accept USP or Ph. Eur. specifications subject to local filing and quality requirements.

What patents protect dehydrated alcohol?

Dehydrated alcohol itself generally has no meaningful composition patent estate. Ethanol is an established chemical, and the commercial product is normally protected by specifications, manufacturing know-how, trademarks, and regulatory qualification rather than by molecule patents.

What formulations are protected by ethanol-related patents?

Patent protection may apply to:

• Drug formulations containing ethanol
• Transdermal or topical delivery systems
• Aerosol compositions
• Injectable co-solvent systems
• Botanical extraction methods
• Dehydration or purification processes
• Packaging systems that reduce evaporation
• Stabilized alcohol-containing compositions

These rights generally protect the drug product, delivery system, manufacturing process, or use rather than dehydrated alcohol as a standalone excipient.

How strong is the patent estate for pharmaceutical ethanol?

The standalone patent estate is weak. The manufacturing and commercial moat can still be meaningful because pharmaceutical buyers require validated suppliers and often avoid changing excipient sources without comparability work.

The strongest protection is operational:

1. Qualified manufacturing sites
2. Consistent impurity profile
3. Regulatory documentation
4. Customer-specific quality agreements
5. Reliable hazardous-material distribution
6. Low contamination risk
7. Proven change-control history

When does dehydrated alcohol lose exclusivity?

Dehydrated alcohol does not have a conventional patent or regulatory exclusivity date. It is a long-established chemical and is available from multiple qualified suppliers.

Exclusivity may exist indirectly at the finished-product level. A branded drug may have patents or FDA exclusivities covering its active ingredient, formulation, method of use, or dosage form. Those rights can limit generic competition even though the ethanol excipient remains freely available.

What generic entry risks exist for ethanol-containing drugs?

Generic entry risk depends on the finished drug, not on the ethanol supply. Key issues include:

• Whether ethanol is listed as an inactive ingredient
• Whether the generic must match the reference product’s inactive ingredients
• Whether the ethanol concentration affects safety or performance
• Whether the formulation has a nonpublic manufacturing process
• Whether formulation or method-of-use patents are listed in the Orange Book
• Whether a Paragraph IV certification challenges those patents

For approved small-molecule drugs, a generic applicant may file an ANDA with Paragraph IV certification against listed patents. The 30-month stay provisions and patent litigation risk arise under the Hatch-Waxman framework, not from the excipient itself.[5]

What is the Orange Book status of dehydrated alcohol?

Dehydrated alcohol is not generally listed in the Orange Book as an independently protected drug product. The Orange Book lists approved drug products and relevant patents or exclusivity information. Ethanol may appear in the inactive-ingredient composition of a listed product, but that does not give the excipient standalone Orange Book protection.[6]

A finished product containing ethanol may have:

• Drug substance patents
• Formulation patents
• Method-of-use patents
• Device or delivery patents
• Pediatric exclusivity
• New chemical entity exclusivity
• Three-year clinical-investigation exclusivity

The presence of dehydrated alcohol in the formulation does not determine the expiration date of those rights.

Which companies are challenging ethanol-containing drug products?

Paragraph IV challengers target listed patents covering the finished pharmaceutical product. Public litigation must be reviewed at the drug-product level because there is no single litigation docket for dehydrated alcohol.

Typical challengers include generic manufacturers such as Teva, Sandoz, Viatris, Lupin, Dr. Reddy’s Laboratories, Sun Pharma, and Hikma, depending on the product. The relevant analysis requires matching each ANDA, patent certification, and court action to a specific reference-listed drug.

What manufacturing and intellectual-property barriers affect supply?

The central barriers are technical and regulatory.

Water control

Ethanol is hygroscopic and can absorb moisture during storage and transfer. Dehydrated product requires moisture-controlled handling, compatible closures, and validated sampling.

Methanol and volatile impurities

Methanol contamination presents severe safety and regulatory risk. Suppliers must control raw materials, distillation fractions, storage tanks, transfer lines, and packaging. Testing may include gas chromatography and other validated methods.

Denatured versus undenatured product

Denatured ethanol contains approved additives that make it unsuitable for consumption. Pharmaceutical use depends on formulation and jurisdiction. A denatured product may be unacceptable where the denaturant affects safety, taste, route of administration, or regulatory filing.

Flammability and logistics

Ethanol is a flammable liquid. Storage requires fire protection, ventilation, grounding, bonding, compatible containers, and hazardous-material transport controls. These requirements raise the fixed cost of regional distribution.

Validation and supplier change

A finished-drug manufacturer may need to assess:

• Solvent grade and pharmacopoeial compliance
• Impurity comparability
• Extractables and leachables
• Process performance
• Batch-to-batch consistency
• Stability impact
• Regulatory filing consequences

These requirements reduce short-term supplier substitutability even where several vendors offer nominally equivalent material.

How does dehydrated alcohol compare with competing pharmaceutical solvents?

Solvent	Main advantage	Main limitation	Substitution risk to ethanol
Ethanol	Broad regulatory familiarity and volatility	Flammability and alcohol exposure	Baseline
Isopropyl alcohol	Strong solvent and rapid evaporation	Different toxicology and formulation profile	Moderate in topical use
Propylene glycol	Low volatility and strong solvency	Viscosity and tolerability concerns	High in oral liquids
Glycerin	Humectancy and sweet taste	High viscosity	Moderate in oral and topical products
Polyethylene glycol	Broad solvency range	Molecular-weight and impurity concerns	Moderate
Acetone	Strong volatility	Generally unsuitable for many finished drugs	Low
Ethyl acetate	Useful process solvent	Limited finished-dose use	Low

Ethanol retains an advantage where formulators need volatility, broad solvent compatibility, established regulatory precedent, and rapid drying.

What is the commercial outlook for pharmaceutical dehydrated alcohol?

The outlook is stable with moderate growth potential and limited structural pricing power. Pharmaceutical-grade suppliers should benefit from recurring demand and high switching costs, but they remain exposed to commodity ethanol markets.

The strongest commercial strategy is to sell a quality-controlled pharmaceutical material rather than a generic bulk solvent. Product differentiation can come from:

• Low-methanol specifications
• High-purity grades for sensitive formulations
• Small-volume pharmaceutical packaging
• Global pharmacopoeial compliance
• On-site or regional inventory
• Regulatory support
• Dual-source qualification
• Technical assistance for formulation and process validation

Revenue growth is likely to track pharmaceutical production, contract manufacturing, and topical and liquid dosage-form demand. Margin expansion requires premium-grade sales, efficient dehydration, reliable feedstock procurement, and the ability to pass through energy and logistics costs.

Key Takeaways

• Dehydrated alcohol is anhydrous, pharmaceutical-grade ethanol used as a solvent, co-solvent, process medium, and, in some products, an active ingredient.
• The market is mature and fragmented, with economics driven by feedstock, energy, logistics, quality systems, and regulatory compliance.
• No meaningful standalone patent or Orange Book exclusivity protects dehydrated alcohol.
• Finished drugs containing ethanol may have separate formulation, method-of-use, or drug-substance patents.
• Generic and Paragraph IV risk must be assessed at the finished-product level.
• Pharmaceutical-grade suppliers earn premiums through impurity control, documentation, validated production, and supply reliability.
• The financial trajectory is stable but cyclical, with limited volume growth and recurring exposure to commodity ethanol pricing.
• Manufacturing barriers are practical rather than primarily intellectual-property based.

FAQs About Dehydrated Alcohol in Pharmaceuticals

Is dehydrated alcohol the same as absolute ethanol?

Yes. Dehydrated alcohol is commonly called absolute ethanol or anhydrous ethanol. Pharmaceutical identity and purity must be confirmed against the applicable pharmacopoeial standard.

Can dehydrated alcohol be used in injectable drugs?

Yes, but only when the formulation, concentration, route, container system, and impurity profile are justified and controlled. Injectable use requires more extensive qualification than many topical or process applications.

Does dehydrated alcohol have a Drug Master File?

Some suppliers maintain DMFs or equivalent confidential regulatory packages for pharmaceutical alcohol products. A DMF is supplier-specific and does not create exclusivity for ethanol itself.

Is denatured alcohol acceptable as a pharmaceutical excipient?

Not automatically. Acceptability depends on the denaturant, route of administration, finished-product formulation, and jurisdiction. Undenatured or specially controlled pharmaceutical ethanol may be required.

Can a pharmaceutical company switch dehydrated alcohol suppliers without regulatory approval?

A supplier change may require internal comparability, stability, process, and quality assessments. Regulatory filing obligations depend on the finished product, manufacturing impact, and jurisdiction.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Alcohol, dehydrated monograph. USP-NF.
2. U.S. Food and Drug Administration. (2023). Policy for testing of alcohol-based hand sanitizers during the public health emergency. FDA.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
4. European Commission. (2015). Guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use. European Commission.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.